Tatva Chintan Pharma Chem Limited (NSE:TATVA)
India · Delayed Price · Currency is INR 1,156.60
-116.60 (-9.16%)
Jan 23, 2026, 3:30 PM IST
Tatva Chintan Pharma Chem Revenue
Tatva Chintan Pharma Chem had revenue of 1.31B INR in the quarter ending December 31, 2025, with 52.90% growth. This brings the company's revenue in the last twelve months to 4.80B, up 28.53% year-over-year. In the fiscal year ending March 31, 2025, Tatva Chintan Pharma Chem had annual revenue of 3.83B, down -2.74%.
Revenue (ttm)
4.80B
Revenue Growth
+28.53%
P/S Ratio
5.64
Revenue / Employee
7.06M
Employees
679
Market Cap
27.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.83B | -107.90M | -2.74% |
| Mar 31, 2024 | 3.94B | -301.08M | -7.11% |
| Mar 31, 2023 | 4.24B | -100.35M | -2.31% |
| Mar 31, 2022 | 4.34B | 1.33B | 44.38% |
| Mar 31, 2021 | 3.00B | 371.20M | 14.10% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Savita Oil Technologies | 40.16B |
| Laxmi Organic Industries | 28.89B |
| Rossari Biotech | 22.91B |
| S H Kelkar and Company | 22.41B |
| Veedol Corporation | 20.38B |
| Jubilant Agri and Consumer Products | 17.51B |
| NOCIL | 13.15B |
| Neogen Chemicals | 8.00B |